Benzcyclane

Benzcyclane (Bencyclane; Benzcyclan) is a platelet aggregation inhibitor and a vasodilator effective in a variety of peripheral circulation disorders.

Signaling Pathways >> Others >> Others

Research Areas >> Cardiovascular Disease

Benzcyclane, although capable of aggregating platelets by itself at very high concentrations, shows a striking inhibitory effect, over a wide range of concentrations, both on platelet aggregation induced by ADP, epinephrine or collagen and on platelet adhesiveness to glass or collagen. Clot retraction is also clearly inhibited[1]. Benzcyclane induces use-dependent inhibition of Na channels in muscle, similarly as do class 1 antiarrhytnmic drugs. Inhibition was observed with both normal and cevadine-modified Na channels[2].

[1]. Ponari O, et al. In vitro effects of bencyclan on coagulation, fibrinolysis and platelet function. Arzneimittelforschung. 1976;26(8):1532-8.

[2]. Nánási PP, et al. Effects of bencyclane on normal and cevadine-modified Na channels in frog skeletal muscle. Gen Physiol Biophys. 1989 Oct;8(5):447-58.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline